TrialBritish journal of haematology2017

A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.

Ahmed Sawas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.